"Cystic Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
Descriptor ID |
D003550
|
MeSH Number(s) |
C06.689.202 C08.381.187 C16.320.190 C16.614.213
|
Concept/Terms |
Pancreatic Cystic Fibrosis- Pancreatic Cystic Fibrosis
- Cystic Fibrosis, Pancreatic
- Fibrocystic Disease of Pancreas
- Pancreas Fibrocystic Disease
- Pancreas Fibrocystic Diseases
- Cystic Fibrosis of Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis".
This graph shows the total number of publications written about "Cystic Fibrosis" by people in this website by year, and whether "Cystic Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2006 | 1 | 1 | 2 |
2012 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2017 | 1 | 1 | 2 |
2018 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2020 | 1 | 0 | 1 |
2021 | 2 | 1 | 3 |
2023 | 2 | 0 | 2 |
2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cystic Fibrosis" by people in Profiles.
-
Advanced cystic fibrosis liver disease: Endovascular, endoscopic, radiologic, and surgical considerations. Pediatr Pulmonol. 2024 Sep; 59 Suppl 1:S115-S122.
-
Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor. Pediatr Pulmonol. 2024 Jul; 59(7):2051-2054.
-
Cystic fibrosis fitness during inpatient treatment (CF-FIT): A pre-post pilot study. Pediatr Pulmonol. 2023 09; 58(9):2675-2677.
-
Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis. Pediatr Pulmonol. 2023 05; 58(5):1592-1594.
-
Hypoplasia of Extrahepatic Biliary Tree and Intrahepatic Cholangiolopathy in Cystic Fibrosis Imperfectly Mimic Biliary Atresia in 4 Infants With Cystic Fibrosis and Kasai Portoenterostomy. Am J Surg Pathol. 2021 11 01; 45(11):1499-1508.
-
Calcium-Regulated Protein CarP Responds to Multiple Host Signals and Mediates Regulation of Pseudomonas aeruginosa Virulence by Calcium. Appl Environ Microbiol. 2021 04 27; 87(10).
-
A dyadic approach to the delineation of diagnostic entities in clinical genomics. Am J Hum Genet. 2021 01 07; 108(1):8-15.
-
Effect of CFTR modulator therapy on cystic fibrosis-related diabetes. J Diabetes Complications. 2021 06; 35(6):107845.
-
Pseudoxanthomonas winnipegensis sp. nov., derived from human clinical materials and recovered from cystic fibrosis and other patient types in Canada, and emendation of Pseudoxanthomonas spadix Young et al. 2007. Int J Syst Evol Microbiol. 2020 Dec; 70(12):6313-6322.
-
The Use of Exaggerative Language in News Articles About Cystic Fibrosis Therapies : Exaggerative Language Describing Cystic Fibrosis Therapies. J Gen Intern Med. 2021 05; 36(5):1437-1439.